Coverage of the Phase 1/2a trial of AAV-delivered FS344 follistatin gene therapy in Becker muscular dystrophy patients. The majority of patients showed significant gains in six-minute walk distance and stair-climbing tests. Investigator Jerry Mendell called it the first gene therapy clinical trial to demonstrate functional improvement in any form of muscular dystrophy.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.